Peter Hohenberger

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Paolo G. Casali, N. Abecassis, Sebastian Bauer et al. · Annals of Oncology · 2018 · 1.6K citations · Full text

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri, Peter Reichardt, Yoon‐Koo Kang et al. · The Lancet · 2012 · 1.4K citations · Full text

Gastrointestinal Oncology, Medicine, Pharmacology +6

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Ian Judson, Jaap Verweij, Hans Gelderblom et al. · The Lancet Oncology · 2014 · 1.1K citations · Full text

Metastatic Soft-tissue Sarcoma, Versus Intensified Doxorubicin, Oncology +7

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall et al. · JAMA · 2012 · 955 citations

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne et al. · European Journal of Cancer · 2006 · 893 citations

Oncology, Gastrointestinal Oncology, Medicine +10